GENFIT S.A. American (GNFT) Financials
Newest figures come from the filing for FY2024, filed Apr 29, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GNFT SEC filings page.
GENFIT S.A. American (GNFT) reported $73.4M in revenue for fiscal year 2024, up 73.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
Scored against operating companies for FY2024. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of GENFIT S.A. American's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
GENFIT S.A. American has an operating margin of 4.6%, meaning the company retains $5 of operating profit per $100 of revenue. Among its peers this margin ranks in the lower range, for a profitability score of 12/100. This is up from -69.6% the prior year.
GENFIT S.A. American's revenue surged 73.9% year-over-year to $73.4M, reflecting rapid business expansion. This strong growth earns a score of 96/100.
GENFIT S.A. American's current ratio of 1.23 indicates adequate short-term liquidity, earning a score of 32/100. The company can meet its near-term obligations, though with limited headroom.
GENFIT S.A. American's free cash flow margin of 20.5% results in a low score of 4/100. Capital expenditures of $1.0M absorb a large share of operating cash flow.
GENFIT S.A. American generates a 2.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 17/100. This is up from -42.5% the prior year.
GENFIT S.A. American passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
For every $1 of reported earnings, GENFIT S.A. American generates $10.32 in operating cash flow ($16.1M OCF vs $1.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
GENFIT S.A. American earns $0.70 in operating income for every $1 of interest expense ($3.4M vs $4.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
GENFIT S.A. American generated $73.4M in revenue in fiscal year 2024. This represents an increase of 73.9% from the prior year.
GENFIT S.A. American's EBITDA was $5.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
GENFIT S.A. American reported $1.6M in net income in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
GENFIT S.A. American earned $0.03 per diluted share (EPS) in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
GENFIT S.A. American generated $15.1M in free cash flow in fiscal year 2024, representing cash available after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
GENFIT S.A. American held $84.7M in cash as of fiscal year 2024; no long-term debt figure is on record for that period.
Not reported for fiscal year 2024.
Margins & Returns
GENFIT S.A. American's operating margin was 4.6% in fiscal year 2024, reflecting core business profitability. This is up 74.3 percentage points from the prior year.
GENFIT S.A. American's net profit margin was 2.1% in fiscal year 2024, showing the share of revenue converted to profit. This is up 77.8 percentage points from the prior year.
GENFIT S.A. American's ROE was 2.2% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 44.7 percentage points from the prior year.
Not reported for fiscal year 2024.
Capital Allocation
GENFIT S.A. American invested $48.9M in research and development in fiscal year 2024. This represents a decrease of 5.0% from the prior year.
GENFIT S.A. American invested $1.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 121.3% from the prior year.
Not reported for fiscal year 2024.
GNFT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.4M+73.9% | $42.2M+48.6% | $28.4M-70.7% | $96.9M+920.8% | $9.5M-79.4% | $46.0M+435.7% | $8.6M+4.2% | $8.2M |
| R&D Expenses | $48.9M-5.0% | $51.4M+34.2% | $38.3M-3.7% | $39.8M-44.9% | $72.3M-2.7% | $74.3M-3.2% | $76.8M+17.9% | $65.1M |
| Operating Income | $3.4Mn/m | -$29.4Mn/m | -$29.2M-181.1% | $36.0Mn/m | -$101.4Mn/m | -$64.9Mn/m | -$79.6Mn/m | -$68.2M |
| EBITDA | $5.2Mn/m | -$27.6Mn/m | -$27.2M-169.6% | $39.1Mn/m | -$97.0Mn/m | -$61.3Mn/m | -$77.5M | N/A |
| Interest Expense | $4.8M-3.7% | $5.0M+8.5% | $4.6M-15.3% | $5.5M-61.5% | $14.2M+12.3% | $12.7M+1.0% | $12.6M+352.1% | $2.8M |
| Income Tax | $352K-16.3% | $420Kn/m | -$124K-105.0% | $2.5Mn/m | -$523Kn/m | -$647Kn/m | -$406Kn/m | -$4.1M |
| Net Income | $1.6Mn/m | -$32.0Mn/m | -$25.4M-133.3% | $76.1Mn/m | -$123.8Mn/m | -$73.1Mn/m | -$91.1Mn/m | -$67.0M |
| EPS (Basic) | $0.03n/m | -$0.64n/m | -$0.51-130.0% | $1.71n/m | -$3.18n/m | -$1.98n/m | -$2.92n/m | -$2.15 |
| EPS (Diluted) | $0.03n/m | -$0.64n/m | -$0.51-136.9% | $1.39n/m | -$3.18n/m | -$1.98 | N/A | N/A |
| Diluted Shares (Avg) | 49.95B+0.5% | 49.70B+0.1% | 49.67B-10.7% | 55.61B+43.1% | 38.86B+5.1% | 36.99B+118576.0% | 31M0.0% | 31M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses.
GNFT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $156.7M-18.5% | $192.3M-16.6% | $230.6M-27.7% | $318.9M+31.6% | $242.3M-30.3% | $347.9M+32.3% | $262.9M-25.4% | $352.5M |
| Current Assets | $96.0M-23.3% | $125.1M-26.2% | $169.5M-44.1% | $303.4M+34.3% | $225.9M-30.8% | $326.4M+30.6% | $249.9M-26.7% | $340.9M |
| Cash & Equivalents | $84.7M-1.6% | $86.1M-40.9% | $145.5M-50.3% | $292.9M+40.0% | $209.2M-32.7% | $310.7M+30.9% | $237.4M-27.9% | $329.2M |
| Inventory | $4K-6.4% | $4K+3.4% | $4K-5.5% | $5K-7.5% | $5K+8.9% | $4K-2.0% | $5K-4.7% | $5K |
| Accounts Receivable | $7.8M-78.4% | $36.2M+112.6% | $17.0M+107.8% | $8.2M-43.8% | $14.6M+7.9% | $13.5M+34.1% | $10.1M+5.3% | $9.6M |
| Total Liabilities | $85.1M-27.4% | $117.2M-9.5% | $129.5M-29.7% | $184.1M-29.9% | $262.4M+3.5% | $253.5M+6.1% | $238.9M+3.6% | $230.5M |
| Current Liabilities | $77.8M+82.8% | $42.6M+1.1% | $42.1M-40.8% | $71.1M+87.2% | $38.0M-22.5% | $49.0M+9.0% | $45.0M+38.0% | $32.6M |
| Non-Current Liabilities | $7.3M-90.2% | $74.6M-14.6% | $87.3M-22.7% | $112.9M-49.7% | $224.4M+9.7% | $204.5M+5.4% | $193.9M-2.0% | $197.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | $14.5M-13.4% | $16.8M+101.8% | $8.3M-0.9% | $8.4M |
| Total Equity | $71.7M-4.7% | $75.2M-25.7% | $101.1M-25.0% | $134.8Mn/m | -$20.1M-121.3% | $94.4M+293.5% | $24.0M-80.3% | $122.0M |
| Retained Earnings | N/A | N/A | N/A | N/A | -$371.3Mn/m | -$267.6Mn/m | -$182.0Mn/m | -$123.3M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.
GNFT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $16.1Mn/m | -$61.3Mn/m | -$77.7M-168.7% | $113.1Mn/m | -$117.9Mn/m | -$53.5Mn/m | -$64.2M | N/A |
| Depreciation & Amortization | $1.8M-2.5% | $1.8M-6.6% | $2.0M-36.8% | $3.1M-28.7% | $4.4M+18.8% | $3.7M+75.8% | $2.1M | N/A |
| Capital Expenditures | $1.0M+121.3% | $458K+70.6% | $269K-42.3% | $465K-57.7% | $1.1M-51.7% | $2.3M-32.3% | $3.4M | N/A |
| Free Cash Flow | $15.1Mn/m | -$61.8Mn/m | -$78.0M-169.2% | $112.6Mn/m | -$119.0Mn/m | -$55.8Mn/m | -$67.6M | N/A |
| Investing Cash Flow | -$1.1M-143.5% | $2.5Mn/m | -$49.5Mn/m | -$3.8Mn/m | -$1.2M-421.8% | $367Kn/m | -$4.6M | N/A |
| Financing Cash Flow | -$10.9Mn/m | -$5.6Mn/m | -$4.1Mn/m | -$10.1Mn/m | -$10.1M-107.7% | $131.2Mn/m | -$7.5M | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
GNFT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 4.6%+74.3pp | -69.6% | -102.7% | 37.2% | -1068.5% | -141.2% | -927.2% | -826.9% |
| Net Margin | 2.1%+77.8pp | -75.7%+13.6pp | -89.3%-167.9pp | 78.6% | -1304.7% | -159.0% | -1061.1% | -812.8% |
| Return on Equity | 2.2%+44.7pp | -42.5%-17.4pp | -25.1%-81.6pp | 56.5% | N/A | -77.5%+302.3pp | -379.8%-324.8pp | -54.9% |
| Return on Assets | 1.0%+17.6pp | -16.6%-5.6pp | -11.0%-34.9pp | 23.9%+75.0pp | -51.1%-30.1pp | -21.0%+13.6pp | -34.6%-15.6pp | -19.0% |
| Current Ratio | 1.23-1.7x | 2.94-1.1x | 4.02-0.2x | 4.27-1.7x | 5.95-0.7x | 6.66+1.1x | 5.56-4.9x | 10.46 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | 0.18-0.2x | 0.35+0.3x | 0.07 |
| Liabilities-to-Equity | 1.19-0.4x | 1.56+0.3x | 1.28-0.1x | 1.37 | N/A | 2.69-7.3x | 9.96+8.1x | 1.89 |
| Asset Turnover | 0.47+0.2x | 0.22+0.1x | 0.12-0.2x | 0.30+0.3x | 0.04-0.1x | 0.13+0.1x | 0.030.0x | 0.02 |
| FCF Margin | 20.5% | -146.3% | -274.4% | 116.3% | -1253.8% | -121.4% | -787.5% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| GENFIT S.A. American GNFT | FY2024 | $73.4M | $1.6M | 2.1% | N/A | 34/100 |
| Kymera Therapeutics, Inc. KYMR | FY2025 | $39.2M | -$311.4M | N/A | $11.2B | 58/100 |
| Protagonist Therapeutics, Inc PTGX | FY2025 | $46.0M | -$130.1M | N/A | $8.5B | 78/100 |
| Viridian Therapeutics, Inc. VRDN | FY2025 | $70.8M | -$342.6M | N/A | $3.2B | 68/100 |
| Zymeworks Inc. ZYME | FY2025 | $106.0M | -$81.1M | -76.6% | $2.1B | 78/100 |
| uniQure N.V. QURE | FY2025 | $16.1M | -$199.0M | N/A | $1.5B | 58/100 |
Where GENFIT S.A. American Ranks
Frequently Asked Questions
GENFIT S.A. American (GNFT) reported $73.4M in total revenue for fiscal year 2024. This represents a 73.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
GENFIT S.A. American (GNFT) revenue grew by 73.9% year-over-year, from $42.2M to $73.4M in fiscal year 2024.
Yes, GENFIT S.A. American (GNFT) reported a net income of $1.6M in fiscal year 2024, with a net profit margin of 2.1%.
GENFIT S.A. American (GNFT) had EBITDA of $5.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
GENFIT S.A. American (GNFT) had an operating margin of 4.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
GENFIT S.A. American (GNFT) had a net profit margin of 2.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
GENFIT S.A. American (GNFT) has a return on equity of 2.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
GENFIT S.A. American (GNFT) generated $15.1M in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
GENFIT S.A. American (GNFT) generated $16.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
GENFIT S.A. American (GNFT) had $156.7M in total assets as of fiscal year 2024, including both current and long-term assets.
GENFIT S.A. American (GNFT) invested $1.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
GENFIT S.A. American (GNFT) invested $48.9M in research and development during fiscal year 2024.
GENFIT S.A. American (GNFT) had a current ratio of 1.23 as of fiscal year 2024, which is considered adequate.
GENFIT S.A. American (GNFT) had a liabilities-to-equity ratio of 1.19 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2024, because the filing data we hold for that year carries no long-term debt figure.
GENFIT S.A. American (GNFT) had a return on assets of 1.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
GENFIT S.A. American (GNFT) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
GENFIT S.A. American (GNFT) has an earnings quality ratio of 10.32x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
GENFIT S.A. American (GNFT) has an interest coverage ratio of 0.70x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
GENFIT S.A. American (GNFT) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.